Please wait while the transcript is being prepared...
0:00
Thanks for having me here.
My name is Dimitri Drekonja.
I'm going to be speaking on
evidence-based treatments
of pyelonephritis,
and other urinary
tract infections.
I'm the Chief of
Infectious Diseases here
at the Minneapolis VA
Health Care System.
Also, Associate
Professor of Medicine
at the University of Minnesota.
I come to this from
the perspective
of someone who conducts
clinical trials,
particularly in the area of
urinary tract infections
trying to find really
the best evidence-based
for treating patients
that we see clinically.
0:31
Briefly, for disclosures only
some grant funding from
the Department of
Veterans Affairs,
from VA Merit Review, and from
the VA Cooperative
Studies Program.
No pharmaceutical affiliations.
0:44
This is the outline of what's
going to be covered here.
First, going to go through
some background in
epidemiology of urinary
tract infections.
Then we'll go into
what's in the name.
Really, not everything
that is put
under the moniker
of UTI is the same.
I think it's important
to use precise language
because when we use
that catch-all term,
we lose any of
the specificity that the
different syndromes have and
there's quite a bit of
prognostic information and
treatment information in there.
The specific clinical
syndromes that we'll go over
are cystitis, AKA lower UTI.
Then, moving on to
pyelonephritis,
which also gets the
number of upper UTIs.
Then, we'll move
into febrile UTI,
which has various
sub-classifications
including a couple of important
ones that I have here,
urosepsis, and emphysematous
pyelonephritis.
Something that I'll explain
what the acronym means there.
But we'll call it BPCUS for now.
Then, moving onto
asymptomatic bacteriuria.
I will briefly
mention prostatitis,
which really deserves its own
lecture in its own right.
Finally, going to close
out with a term that
vexes everybody
in the UTI field.
That is the term complicated.
What exactly is a
complicated UTI?
What do we mean by
that? Do people
mean the same things
when they use that term?
Then, we'll summarize
the take-home points and
hopefully, leave with a
good overall understanding.
